Shingles Vaccine Timing with JAK Inhibitors
For the recombinant zoster vaccine (Shingrix), hold JAK inhibitors for 1 week after each vaccine dose; if giving the live zoster vaccine (Zostavax), administer it at least 3-4 weeks before starting JAK inhibitors. 1
Recombinant Zoster Vaccine (Shingrix) - Preferred Option
The recombinant zoster vaccine is the preferred choice because it is non-live and can be safely administered to immunosuppressed patients 1, 2. This is critical since JAK inhibitors significantly increase herpes zoster risk, with incidence rates of 4-8 per 100 person-years in real-world cohorts 3, 4.
Timing Protocol for Shingrix:
Before starting JAK inhibitors:
- Ideally complete the 2-dose series (doses given 2-6 months apart) before initiating therapy 1
- If time-sensitive, give at least the first dose at least 14 days before starting JAK inhibitors 5
- For immunocompromised patients, the interval between doses can be shortened to 1-2 months 6, 5
After each vaccine dose:
- Hold JAK inhibitor for 1 week after vaccination to allow adequate immune response 7, 8
- This applies to both the first and second doses
- The European Task Force recommends this 1-week pause specifically to prevent insufficient vaccination response 1
If already on JAK inhibitors:
- Vaccination can still be given while on therapy 1
- Hold the JAK inhibitor for 1 week after each dose 8
- Studies show vaccine effectiveness of approximately 59% in patients on JAK inhibitors, though this varies by specific agent 4
Live Zoster Vaccine (Zostavax) - Alternative When Shingrix Unavailable
If the recombinant vaccine is not available, the live zoster vaccine requires different timing:
Before starting JAK inhibitors:
- Administer at least 3-4 weeks before initiating JAK inhibitor therapy 1
- This allows time for immune response establishment before immunosuppression begins
After vaccination:
- Hold JAK inhibitor for 4 weeks after live vaccine administration 9
Contraindication:
- Never give live zoster vaccine during JAK inhibitor therapy 2, 10
- Wait at least 3 months after stopping JAK inhibitors before administering live vaccine 2
Critical Clinical Considerations
High-Risk Populations Requiring Vaccination:
- All patients ≥50 years starting JAK inhibitors 2, 10
- Patients ≥18 years starting JAK inhibitors (particularly important given increased zoster risk) 2
- Patients with diabetes mellitus or chronic kidney disease have 3-fold higher herpes zoster risk on JAK inhibitors 3
Common Pitfall:
Real-world data shows only 9.9-27.5% of JAK inhibitor patients receive zoster vaccination 11, 3, and timing rarely coincides with therapy initiation 11. Proactive vaccination planning is essential - ideally address this before prescribing JAK inhibitors rather than waiting for the patient to develop herpes zoster.
Disease Activity Considerations:
While guidelines recommend completing vaccination before starting JAK inhibitors, clinical scenarios often make treatment delays challenging 1. In urgent situations where disease activity necessitates immediate JAK inhibitor initiation, give the first Shingrix dose and start the JAK inhibitor, then hold for 1 week after the second dose 1-2 months later.
Vaccine Effectiveness:
No herpes zoster cases were observed in vaccinated patients in some cohorts 3, though overall effectiveness is approximately 59% in JAK inhibitor-treated patients 4. The vaccine shows better humoral than cellular responses in immunosuppressed patients 12, but remains the best available prevention strategy.